(MDGL) Madrigal Pharmaceuticals - Ratings and Ratios

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company dedicated to addressing metabolic dysfunction-associated steatohepatitis (MASH), a severe form of non-alcoholic steatohepatitis (NASH) characterized by liver inflammation and fibrosis. The companys lead product, Rezdiffra (rezvilutamide), is a liver-directed thyroid hormone receptor beta (THR-β) agonist designed to target the underlying causes of MASH by enhancing fatty acid oxidation and reducing liver fat. Headquartered in West Conshohocken, Pennsylvania, Madrigal focuses on developing innovative therapies for chronic liver diseases with high unmet medical need. Web URL: https://www.madrigalpharma.com

Based on clinical data, Rezdiffra has shown promise in reducing liver fat and improving histological measures in patients with MASH. The drugs mechanism of action involves selectively activating THR-β, which plays a critical role in regulating lipid metabolism and energy expenditure in the liver. This targeted approach may offer advantages over broader-acting thyroid hormone receptor agonists, potentially minimizing systemic side effects. Madrigal is also exploring additional indications for Rezdiffra, further expanding its pipeline.

Madrigal Pharmaceuticals, Inc. is listed on the NASDAQ under the ticker symbol MDGL. The company operates in the biotechnology sector and is classified under the GICS Sub Industry category of biotechnology. For more information, visit their official website: https://www.madrigalpharma.com

Over the next three months, Madrigal Pharmaceuticals stock is expected to remain volatile, influenced by clinical trial updates and broader market trends in the biotechnology sector. Based on the provided , the stock is trading at $319.93 with a 20-day average volume of 337,034 shares. The short-term moving averages (SMA20: 316.38) suggest a bullish crossover, while the longer-term SMA200 (290.15) indicates upward momentum. The ATR of 17.63 signals moderate volatility, with potential price fluctuations within a range of $300-$340. From a perspective, the companys market cap of $6,660.71M reflects investor confidence in its pipeline, despite the negative return on equity (-61.76%). The price-to-book ratio (P/B: 8.83) and price-to-sales ratio (P/S: 36.98) highlight the markets valuation of its assets and revenue potential. However, the lack of P/E and forward P/E ratios underscores the companys current focus on growth over profitability.